Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS

Authors not listed

Medstar Health Research Institute · 2006

Abstract

The primary objective of this clinical trial is to assess the efficacy of rosiglitazone on bare metal stent (BMS) in-stent restenosis measured as late lumen loss in patients with metabolic syndrome. The secondary parameter for evaluation of efficacy is binary restenosis. The tertiary objective will be to assess the effect of rosiglitazone on major cardiac events (MACE; death, MI, CABG, and target vessel revascularization). The occurrence of in-stent restenosis for patients with metabolic syndrome who receive a DES in a non-target lesion will be assessed angiographically at 9 months.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-13 MST

Cite this

APA
Anonymous. (2006). Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS. <em>Medstar Health Research Institute</em>. https://clinicaltrials.gov/study/NCT00465296
Vancouver
Anonymous. Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS. Medstar Health Research Institute. 2006.
BibTeX
@misc{anon2006PparGa, title = {Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS}, author = {Anonymous}, journal = {Medstar Health Research Institute}, year = {2006}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings